Patents by Inventor Keith REIMANN

Keith REIMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20220387587
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 8, 2022
    Inventors: Bo YU, Rijian Wang, Keith Reimann
  • Polynucleotides encoding a humanized anti-CD40 antibody
    Patent number: 11439706
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: September 13, 2022
    Assignee: Primatope Therapeutics Inc.
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20200384107
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 10, 2020
    Inventors: Bo YU, Rijian WANG, Keith REIMANN
  • Humanized anti-CD40 antibodies and methods of administering thereof
    Patent number: 10772958
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: September 15, 2020
    Assignee: Primatope Therapeutics Inc.
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • HUMANIZED ANTI-CD40 ANTIBODIES AND METHODS OF ADMINISTERING THEREOF
    Publication number: 20190117771
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: December 27, 2018
    Publication date: April 25, 2019
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • Polynucleotides encoding humanized anti-CD40 antibodies
    Patent number: 10201608
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 12, 2019
    Assignee: Primatope Therapeutics Inc.
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20180280507
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: April 17, 2018
    Publication date: October 4, 2018
    Inventors: Bo Yu, Rijian WANG, Keith REIMANN
  • Humanized anti-CD40 antibodies and methods of administering thereof
    Patent number: 9974855
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 22, 2018
    Assignee: Primatope Therapeutics Inc.
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20180078640
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Bo Yu, Rijian WANG, Keith REIMANN